低剂量尼洛替尼可维持FIP1L1/PDGFRA阳性高嗜酸性粒细胞综合征的完全分子缓解。 - Suppr

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

作者信息

Tabouret Emeline, Charbonnier Aude, Mozziconacci Marie-Joelle, Ivanov Vadim

出版信息

Leuk Res. 2011 Jan;35(1):136. doi: 10.1016/j.leukres.2010.08.004. Epub 2010 Sep 15.

DOI:10.1016/j.leukres.2010.08.004

PMID:20832858

Abstract

摘要

相似文献

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

Leuk Res. 2011 Jan;35(1):136. doi: 10.1016/j.leukres.2010.08.004. Epub 2010 Sep 15.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26.

[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):448-52.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

N Engl J Med. 2003 Mar 27;348(13):1201-14. doi: 10.1056/NEJMoa025217.

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15.

Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.

[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].

Rev Med Interne. 2008 Jan;29(1):65-7. doi: 10.1016/j.revmed.2007.09.036. Epub 2007 Oct 25.

[A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].

Ned Tijdschr Geneeskd. 2006 May 27;150(21):1188-92.

[Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].

Ann Biol Clin (Paris). 2005 May-Jun;63(3):317-22.

[A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].

Ned Tijdschr Geneeskd. 2006 Sep 2;150(35):1936-43.

引用本文的文献

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):326-331. doi: 10.1182/asheducation-2018.1.326.

How I treat hypereosinophilic syndromes.

Blood. 2015 Aug 27;126(9):1069-77. doi: 10.1182/blood-2014-11-551614. Epub 2015 May 11.

Management of hypereosinophilia in tropical settings.

Med J Armed Forces India. 2015 Jan;71(1):60-6. doi: 10.1016/j.mjafi.2014.11.008. Epub 2014 Dec 25.

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. doi: 10.1007/s00432-013-1529-7. Epub 2013 Sep 22.

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.

J Blood Med. 2013 Aug 9;4:111-21. doi: 10.2147/JBM.S33142. eCollection 2013.

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Expert Rev Hematol. 2012 Apr;5(2):157-76. doi: 10.1586/ehm.11.81.

Therapeutic approaches to patients with hypereosinophilic syndromes.

Semin Hematol. 2012 Apr;49(2):160-70. doi: 10.1053/j.seminhematol.2012.01.002.

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

PLoS One. 2012;7(2):e30567. doi: 10.1371/journal.pone.0030567. Epub 2012 Feb 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

作者信息

出版信息

相似文献

引用本文的文献